Novo Nordisk supply of Wegovy stabilizes as FDA shortage ends

Key Takeaways

• FDA’s February 21, 2025 declaratory order ended the Wegovy and Ozempic shortage that began in 2022.
• FDA said Novo Nordisk’s stated availability and manufacturing capacity can meet present and projected U.S. demand.
• Compounding enforcement discretion ran to April 22, 2025 (503A) and May 22, 2025 (503B).
• Novo Nordisk cited continuous shipping of all doses and about $6.5 billion of U.S. investment that year.

When did FDA resolve the Wegovy shortage?

FDA determined on February 21, 2025 that the shortage of semaglutide injection products is resolved. Wegovy had been listed since March 2022 and Ozempic since August 2022. The agency’s public order states supply meets or exceeds current demand and, on best judgment of available data, projected demand.

Primary documentation is the FDA declaratory order (media/185526) and the companion FDA compounder policy statement.

What changed for compounders after shortage resolution?

Once a drug leaves FDA’s shortage list, federal limits on compounding “essentially a copy” of an approved product generally return. To limit abrupt treatment disruption, FDA described temporary enforcement discretion after the February 21, 2025 announcement.

• 503A state-licensed pharmacies and physicians: through April 22, 2025
• 503B outsourcing facilities: through May 22, 2025
• FDA still warned that intermittent, limited local pharmacy-level disruptions could occur as product moves through distribution

How Novo Nordisk framed U.S. supply capacity

In a February 21, 2025 statement on PR Newswire, Novo Nordisk said FDA confirmed U.S. supply meets or exceeds current and projected demand. The company said all doses of Wegovy and Ozempic were being shipped regularly to wholesalers and cited about $6.5 billion of U.S. manufacturing investments that year.

Those company claims are manufacturer disclosures; FDA’s order rests on confidential supply and inventory submissions that are not fully public.

What Wegovy’s approved U.S. label covers

Wegovy (semaglutide) injection is an FDA-approved GLP-1 receptor agonist for chronic weight management in indicated adults and adolescents, with additional labeled cardiovascular risk-reduction use in adults with established cardiovascular disease and obesity or overweight. Label text is available on DailyMed.

Cardiovascular outcomes evidence includes the SELECT program on ClinicalTrials.gov (NCT03552757), which evaluated major adverse cardiovascular events in adults with overweight or obesity and established cardiovascular disease.

Commercial and access implications

Shortage resolution shifts leverage from compounded semaglutide copies toward branded supply and payer channel design. Prescribers and pharmacies should treat national shortage status as closed while watching local inventory and payer prior-authorization rules. Competitors in the GLP-1 class remain relevant for share, not for the FDA shortage determination itself.

What remains unproven

FDA did not publish unit-level inventory tables in the public order. Localized stockouts can still occur even when national shortage status is resolved. Company investment headlines do not by themselves prove pharmacy fill rates or net patient access after insurance and cash-pay barriers.

Related NovaPharma coverage

• Medicare GLP-1 coverage 2026 Bridge program
• GLP-1 usage statistics and uptake data
• CagriSema Phase 3 obesity results

Frequently Asked Questions

Primary Sources

1. FDA declaratory order: resolution of semaglutide injection shortage (Feb. 21, 2025)
2. FDA: policies for compounders as GLP-1 supply stabilizes
3. PR Newswire: Novo Nordisk on FDA shortage resolution
4. DailyMed: Wegovy (semaglutide) labeling
5. ClinicalTrials.gov: SELECT (NCT03552757)